{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:02:58Z","timestamp":1785240178771,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06118-8","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T23:45:00Z","timestamp":1737589500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia\/lymphoma patient"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-8068","authenticated-orcid":false,"given":"S\u00fcreyya","family":"Yi\u011fit Kaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5191-174X","authenticated-orcid":false,"given":"Mehrad","family":"Vatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0309-4109","authenticated-orcid":false,"given":"Rima","family":"Akil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7685-2766","authenticated-orcid":false,"given":"Tansel","family":"Cakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4766-1861","authenticated-orcid":false,"given":"Senem","family":"Maral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-9462","authenticated-orcid":false,"given":"Leylag\u00fcl","family":"Kaynar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-4113","authenticated-orcid":false,"given":"\u00d6m\u00fcr G\u00f6kmen","family":"Sevindik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"1","key":"6118_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40364-021-00347-z","volume":"9","author":"F Tarantini","year":"2021","unstructured":"Tarantini F, Cumbo C, Anelli L et al (2021) Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick. Biomark Res 9(1):89","journal-title":"Biomark Res"},{"key":"6118_CR2","doi-asserted-by":"crossref","unstructured":"Sin Cfung (2021) Man P Hei M. Early T-Cell Precursor Acute Lymphoblastic Leukemia: diagnosis, updates in Molecular Pathogenesis, Management, and Novel therapies. Front Oncol.;11","DOI":"10.3389\/fonc.2021.750789"},{"issue":"2","key":"6118_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","volume":"14","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Luger SM, Relapsed T, Cell ALL (2019) Current approaches and new directions. Curr Hematol Malig Rep 14(2):83\u201393","journal-title":"Curr Hematol Malig Rep"},{"key":"6118_CR4","doi-asserted-by":"crossref","unstructured":"Castaneda Puglianini O, Papadantonakis N (2020) Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol.;11","DOI":"10.1177\/2040620720929475"},{"issue":"7380","key":"6118_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L et al (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157\u2013163","journal-title":"Nature"},{"issue":"4","key":"6118_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ et al (2020) Clinical experience with Venetoclax Combined with Chemotherapy for relapsed or refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212\u2013218","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"6118_CR7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K et al (2016) Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 128(10):1382\u20131395","journal-title":"Blood"},{"issue":"9","key":"6118_CR8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C et al (2014) Maturation stage of T-cell Acute Lymphoblastic Leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 4(9):1074\u20131087","journal-title":"Cancer Discov"},{"issue":"9","key":"6118_CR9","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1080\/10428194.2021.1897807","volume":"62","author":"S Arora","year":"2021","unstructured":"Arora S, Vachhani P, Bachiashvili K et al (2021) Venetoclax with chemotherapy in relapse\/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 62(9):2292\u20132294","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"6118_CR10","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00277-024-05775-z","volume":"103","author":"H Shi","year":"2024","unstructured":"Shi H, Yang F, Cao M et al (2024) Daratumumab and Venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: Single-arm, open-label, phase I study. Ann Hematol 103(8):2993\u20133004","journal-title":"Ann Hematol"},{"issue":"1","key":"6118_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NWCJ van de Donk","year":"2016","unstructured":"van de Donk NWCJ, Janmaat ML, Mutis T et al (2016) Monoclonal antibodies targeting\u2009<\u2009scp\u2009>\u2009CD\u200938 in hematological malignancies and beyond. Immunol Rev 270(1):95\u2013112","journal-title":"Immunol Rev"},{"issue":"9","key":"6118_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY et al (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 131(9):995\u2013999","journal-title":"Blood"},{"key":"6118_CR13","doi-asserted-by":"crossref","unstructured":"Prejzner W, Pieko\u015b O, Be\u0142dzi\u0144ska K et al (2023) The role of daratumumab in relapsed\/refractory CD38 positive acute leukemias\u2014case report on three cases with a literature review. Front Oncol.;13","DOI":"10.3389\/fonc.2023.1228481"},{"issue":"13","key":"6118_CR14","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ et al (2020) 5-Azacitidine induces NOXA to Prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res 26(13):3371\u20133383","journal-title":"Clin Cancer Res"},{"issue":"13","key":"6118_CR15","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"CL Wan","year":"2021","unstructured":"Wan CL, Zou JY, Qiao M et al (2021) Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma 62(13):3300\u20133303","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"6118_CR16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2023-179733","volume":"142","author":"HY Cao","year":"2023","unstructured":"Cao HY, Chen LL, Wan CL et al (2023) Venetoclax Combined with Azacitidine was effective and safe for Relapsed\/Refractory T-Cell Acute Lymphoblastic Leukemia\/ lymphoblastic lymphoma: preliminary results of a phase 2, Multicenter Trial. Blood 142(Supplement 1):1501\u20131501","journal-title":"Blood"},{"issue":"4","key":"6118_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2021.279851","volume":"107","author":"M Cerrano","year":"2022","unstructured":"Cerrano M, Bonifacio M, Olivi M et al (2022) Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational campus ALL study. Haematologica 107(4):996\u2013999","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06118-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T06:08:29Z","timestamp":1739340509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06118-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":17,"alternative-id":["6118"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06118-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4864091\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent for publication was obtained from the patient. All the authors have reviewed the manuscript and approved it for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}